Conceptualization of fibroblast growth factor receptor 1 targeting nanomedicines

Yilin Ma , Mengqin Guo , Yang Liu , Zhengwei Huang

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002353

PDF (2139KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002353 DOI: 10.37349/etat.2025.1002353
Letter to the Editor
research-article
Conceptualization of fibroblast growth factor receptor 1 targeting nanomedicines
Author information +
History +
PDF (2139KB)

Abstract

Fibroblast growth factor receptor 1 (FGFR1) is crucial in the progression of various cancers, participating in the processes of cell proliferation, survival, and differentiation. FGFR1 plays a role in the resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Therefore, using monoclonal antibodies and tyrosine kinase inhibitors to target FGFR1 and enhancing ICIs by modifying the tumor microenvironment and combating immune suppression represents a potential therapeutic strategy. Based on the FGFR1-related research and the active targeting strategy, we believe that modifying the surface of nanomedicines with anti-FGFR1 antibodies (such as OM-RCA-01) is an effective targeted treatment method for tumors with high expression of FGFR1. Although there have been relevant studies confirming the feasibility of this approach, there are challenges in clinical application, especially in terms of maintaining uniform quality during large-scale production. Therefore, we suggest conducting further optimization studies in the future to accelerate the clinical application of such drug delivery systems and provide more efficient and cost-effective options for tumor treatment.

Keywords

fibroblast growth factor receptor 1 / anti-FGFR1 antibody / cancer targeting / nanomedicine

Cite this article

Download citation ▾
Yilin Ma, Mengqin Guo, Yang Liu, Zhengwei Huang. Conceptualization of fibroblast growth factor receptor 1 targeting nanomedicines. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002353 DOI:10.37349/etat.2025.1002353

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Tsimafeyeu I. Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy. Explor Target Antitumor Ther. 2025; 6: 1002327.

[2]

Hu Y, Lu Y, Xing F, Hsu W. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression. Cancer Lett. 2022; 547: 215867.

[3]

Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs. 2013; 31: 1436-43.

[4]

Wakaskar RR. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 2018; 26: 311-8.

[5]

Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer. 1993; 67: 975-80.

[6]

Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol. 2014; 2: 904-8.

[7]

Jariwala DH, Patel D, Wairkar S. Surface functionalization of nanodiamonds for biomedical applications. Mater Sci Eng C Mater Biol Appl. 2020; 113: 110996.

[8]

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20: 101-24.

[9]

Cheng WWK, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2008; 126: 50-8.

[10]

Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008; 60: 1615-26.

[11]

Bazak R, Houri M, Achy SE, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015; 141: 769-84.

[12]

Srinivasarao M, Low PS. Ligand-Targeted Drug Delivery. Chem Rev. 2017; 117: 12133-64.

[13]

Nguyen PV, Allard-Vannier E, Chourpa I, Hervé-Aubert K. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control. Int J Pharm. 2021; 605: 120795.

[14]

Jurek PM, Zabłocki K, Waśko U, Mazurek MP, Otlewski J, Jeleń F. Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy. Int J Nanomedicine. 2017; 12: 2941-50.

[15]

Marei HE, Cenciarelli C, Hasan A. Potential of antibody‒drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022; 22: 255.

[16]

Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y, et al. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers. Mol Cancer. 2024; 23: 62.

[17]

Kamankesh M, Yadegar A, Llopis-Lorente A, Liu C, Haririan I, Aghdaei HA, et al. Future Nanotechnology-Based Strategies for Improved Management of Helicobacter pylori Infection. Small. 2024; 20: e2302532.

PDF (2139KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉